Evoke Pharma EPS - Earnings per Share 2012-2024 | EVOK

Evoke Pharma eps - earnings per share from 2012 to 2024. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
Evoke Pharma Annual EPS
2023 $-27.97
2022 $-31.45
2021 $-38.18
2020 $-74.94
2019 $-46.12
2018 $-66.29
2017 $-129.70
2016 $-165.73
2015 $-269.50
2014 $-317.05
2013 $-172.94
2012 $-257.97
2011 $-314.17
Evoke Pharma Quarterly EPS
2024-09-30 $-0.94
2024-06-30 $-0.93
2024-03-31 $-2.04
2023-12-31 $-7.14
2023-09-30 $-6.08
2023-06-30 $-6.71
2023-03-31 $-8.04
2022-12-31 $-6.12
2022-09-30 $-7.20
2022-06-30 $-8.52
2022-03-31 $-9.60
2021-12-31 $-7.68
2021-09-30 $-8.76
2021-06-30 $-10.20
2021-03-31 $-11.53
2020-12-31 $-12.97
2020-09-30 $-11.53
2020-06-30 $-40.35
2020-03-31 $-10.09
2019-12-31 $-7.21
2019-09-30 $-10.09
2019-06-30 $-12.97
2019-03-31 $-15.85
2018-12-31 $-14.41
2018-09-30 $-12.97
2018-06-30 $-20.18
2018-03-31 $-18.74
2017-12-31 $-8.65
2017-09-30 $-49.00
2017-06-30 $-18.74
2017-03-31 $-53.32
2016-12-31 $0.00
2016-09-30 $-41.79
2016-06-30 $-59.09
2016-03-31 $-64.85
2015-12-31 $-50.44
2015-09-30 $-60.53
2015-06-30 $-74.94
2015-03-31 $-83.59
2014-12-31 $-70.62
2014-09-30 $-90.79
2014-06-30 $-85.03
2014-03-31 $-70.62
2013-12-31 $-20.18
2013-09-30 $-59.09
2013-06-30 $-30.26
2013-03-31 $-63.41
2012-12-31 $0.00
2012-09-30 $-61.97
2012-06-30 $0.00
2011-12-31 $0.00
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.007B $0.005B
Evoke Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. The Company's lead product candidate, EVK-001, is in late stage clinical testing which is intended for the treatment of diabetic gastroparesis. Evoke Pharma, Inc. is based in San Diego, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.044B 6.25
Dr Reddy's Laboratories (RDY) India $11.978B 22.92
BridgeBio Pharma (BBIO) United States $4.260B 0.00
Bausch Health Cos (BHC) Canada $3.012B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.097B 12.61
Supernus Pharmaceuticals (SUPN) United States $1.962B 26.71
Taysha Gene Therapies (TSHA) United States $0.434B 30.29
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.098B 0.00
Sol-Gel Technologies (SLGL) Israel $0.012B 0.00
Teligent (TLGT) United States $0.000B 0.00